Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

ClinicalTrials.gov ID: NCT05044195

Public ClinicalTrials.gov record NCT05044195. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 6:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Observer-blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine in Comparison With a Licensed Quadrivalent Influenza Vaccine, in Adults 50 to 64 Years of Age

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 3 study is a randomized, observer-blind immunogenicity and safety study of aQIV (an MF59-adjuvanted quadrivalent influenza vaccine) compared with a licensed quadrivalent influenza vaccine in adults 50 to 64 years of age.

Study identification

NCT ID
NCT05044195
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Seqirus
Industry
Enrollment
2,044 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
50 Years to 64 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 29, 2021
Primary completion
Jan 17, 2022
Completion
Sep 8, 2022
Last update posted
Sep 27, 2023

2021 – 2022

United States locations

U.S. sites
12
U.S. states
8
U.S. cities
12
Facility City State ZIP Site status
84013 Coastal Clinical Research, Inc. Mobile Alabama 36608
84007 Alliance for Multispecialty Research Tempe Arizona 85281
84005 JEM Research Institute Atlantis Florida 33462
84010 Headlands Research Orlando Orlando Florida 32819
84001 Meridian Clinical Research Savannah Georgia 31406
84003 Meridian Clinical Research Sioux City Iowa 51106
84006 Alliance for Multispecialty Research Kansas City Missouri 64114
84009 Meridian Clinical Research Lincoln Nebraska 68510
84002 Meridian Clinical Research Norfolk Nebraska 68701
84004 Meridian Clinical Research Omaha Nebraska 68134
84008 United Medical Associates Binghamton New York 13901
84011 Meridian Clinical Research Endwell New York 13760

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05044195, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 27, 2023 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05044195 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →